Experts Divided Over Link Between Vytorin, Cancer

September 2, 2008

Medical experts are divided over the possible link between the Merck & Co and Schering-Plough cholesterol drug Vytorin, and the risk of developing cancer..Washington (ChattahBox) – Medical experts are divided over the possible link between the Merck & Co and Schering-Plough cholesterol drug Vytorin, and the risk of developing cancer..

This week, a brand new editorial was publsihed in the New England Journal of Medicine, taking a look at the safety of Vytorin, and its link to cancer.

The editorial was aimed at a previously released analysis which virtually dismissed any type of link between Vytorin, and an increased risk of cancer.

A study that was carried out on the cholesterol drug Vytorin compared patients on the drug, to those taking a placebo.

They found that patients taking the drug developed 50% more cancer cases, compared directly those taking a placebo.

The analysis that was done though, which included 2 other stories, found no link between cancer and Vytorin.

This study, SEAS is published in the New England Journal of Medicine.

The debate wages on over the drugs’ safety, as the report will be presented at the annual conference of the European Society of Cardiology.


Comments

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.